Specify a stock or a cryptocurrency in the search bar to get a summary
Soleno Therapeutics Inc
SLNOSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. Address: 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065
Analytics
WallStreet Target Price
74.25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SLNO
Dividend Analytics SLNO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SLNO
Stock Valuation SLNO
Financials SLNO
Results | 2019 | Dynamics |